Skip to menu Skip to content Skip to footer
Dr Eva Baxter
Dr

Eva Baxter

Email: 
Phone: 
+61 7 334 66049

Overview

Background

Dr Baxter is a Research Fellow at the Queensland Centre for Gynaecological Cancer (QCGC) Research. The major theme of her research is to identify and validate biomarkers that improve outcomes for females with gynaecological cancer, particularly endometrial cancer. Dr Baxter leads the translational studies for two clinical trials: the recently completed feMMe phase II randomised clinical trial which showed that approximately 60% of females with early-stage endometrial cancer can safely avoid a hysterectomy and instead undergo hormonal (intrauterine progestin) treatment (NCT01686126), and the ongoing ENDO-3 phase III randomised clinical trial which explores the risks and benefits of sentinel node biopsy in early-stage endometrial cancer (NCT04073706).

Availability

Dr Eva Baxter is:
Available for supervision
Media expert

Qualifications

  • Doctor of Philosophy, University of Edinburgh

Research interests

  • Endometrial cancer

  • Biomarkers

  • Molecular biology

Works

Search Professor Eva Baxter’s works on UQ eSpace

11 works between 2014 and 2025

1 - 11 of 11 works

2025

Journal Article

A Phase 2b, open-label, single arm, multicentre, pilot study of the efficacy, safety and tolerability of dostarlimab in women with early-stage MMR deficient endometrioid endometrial adenocarcinoma

Obermair, A., Gebski, V., Goh, J., Kuchel, A., Brand, A., Mak, B., McNally, O., Baxter, E., Jobling, T. and Mileshkin, L. (2025). A Phase 2b, open-label, single arm, multicentre, pilot study of the efficacy, safety and tolerability of dostarlimab in women with early-stage MMR deficient endometrioid endometrial adenocarcinoma. International Journal of Gynecological Cancer, 35 (4) 101644, 101644. doi: 10.1016/j.ijgc.2025.101644

A Phase 2b, open-label, single arm, multicentre, pilot study of the efficacy, safety and tolerability of dostarlimab in women with early-stage MMR deficient endometrioid endometrial adenocarcinoma

2024

Conference Publication

EV430/#358  Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis

Obermair, Andreas, West, Zoe, Baxter, Eva, Condous, George, Hacker, Neville, Lord, Sally, Mccarthy, Sandie, Janda, Monika, Tuffaha, Haitham, Hayes, Sandi, Disipio, Tracey, Mellon, Anne, Gebski, Val, Mcnally, Orla and Martin, Andrew (2024). EV430/#358  Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis. IGCS 2024 Annual Meeting, Dublin, Ireland, 16-18 October 2024. London, United Kingdom: BMJ Group. doi: 10.1136/ijgc-2024-igcs.551

EV430/#358  Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis

2021

Journal Article

A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020

Obermair, Andreas, Nicklin, Jim, Gebski, Val, Hayes, Sandra C., Graves, Nicholas, Mileshkin, Linda, Lin, Ming Yin, Beale, Phillip, Baxter, Eva, Robledo, Kristy, Salomon, Carlos, Hanna, George B. and Janda, Monika (2021). A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecologic Cancer, 31 (12) ijgc-2021-003029, 1595-1601. doi: 10.1136/ijgc-2021-003029

A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020

2020

Journal Article

Fertility-sparing treatment in early endometrial cancer: current state and future strategies

Obermair, Andreas, Baxter, Eva, Brennan, Donal J., McAlpine, Jessica N., Muellerer, Jennifer J., Amant, Frédéric, van Gent, Mignon D. J. M., Coleman, Robert L., Westin, Shannon N., Yates, Melinda S., Krakstad, Camilla and Janda, Monika (2020). Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 63 (4), 417-431. doi: 10.5468/ogs.19169

Fertility-sparing treatment in early endometrial cancer: current state and future strategies

2020

Journal Article

Improving response to progestin treatment of low-grade endometrial cancer

Baxter, Eva, Brennan, Donal J, McAlpine, Jessica N, Mueller, Jennifer J, Amant, Frédéric, van Gent, Mignon D J M, Huntsman, David G, Coleman, Robert L, Westin, Shannon N, Yates, Melinda S, Krakstad, Camilla, Quinn, Michael A, Janda, Monika and Obermair, Andreas (2020). Improving response to progestin treatment of low-grade endometrial cancer. International Journal of Gynecologic Cancer, 30 (11) ijgc-2020-001309, ijgc-2020. doi: 10.1136/ijgc-2020-001309

Improving response to progestin treatment of low-grade endometrial cancer

2020

Journal Article

Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer

Donohoe, Fionán, Wilkinson, Michael, Baxter, Eva and Brennan, Donal J. (2020). Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer. International Journal of Molecular Sciences, 21 (4) 1241, 1-19. doi: 10.3390/ijms21041241

Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer

2020

Journal Article

G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome

Casciello, Francesco, Al-Ejeh, Fares, Miranda, Mariska, Kelly, Greg, Baxter, Eva, Windloch, Karolina, Gannon, Frank and Lee, Jason S. (2020). G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. Theranostics, 10 (10), 4515-4529. doi: 10.7150/thno.41453

G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome

2019

Journal Article

Molecular basis of distinct oestrogen responses in endometrial and breast cancer

Baxter, Eva, Windloch, Karolina, Kelly, Greg, Lee, Jason S., Gannon, Frank and Brennan, Donal (2019). Molecular basis of distinct oestrogen responses in endometrial and breast cancer. Endocrine-Related Cancer, 26 (1), 31-46. doi: 10.1530/ERC-17-0563

Molecular basis of distinct oestrogen responses in endometrial and breast cancer

2018

Journal Article

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

Jacquelin, Sebastien, Straube, Jasmin, Cooper, Leanne, Vu, Therese, Song, Axia, Bywater, Megan, Baxter, Eva, Heidecker, Matthew, Wackrow, Brad, Porter, Amy, Ling, Victoria, Green, Joanne, Austin, Rebecca, Kazakoff, Stephen, Waddell, Nicola, Hesson, Luke B., Pimanda, John E., Stegelmann, Frank, Bullinger, Lars, Döhner, Konstanze, Rampal, Raajit K., Heckl, Dirk, Hill, Geoffrey R. and Lane, Steven W. (2018). Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood, 132 (26), blood-2018. doi: 10.1182/blood-2018-04-846220

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

2016

Journal Article

Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy

Obermair, Andreas, Brennan, Donal J., Baxter, Eva, Armes, Jane E., Gebski, Val and Janda, Monika (2016). Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. Gynecologic Oncology Research and Practice, 3 (1), 1. doi: 10.1186/s40661-016-0023-8

Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy

2014

Journal Article

Epigenetic regulation in cancer progression

Baxter, Eva, Windloch, Karolina, Gannon, Frank and Lee, Jason S. (2014). Epigenetic regulation in cancer progression. Cell & Bioscience, 4 (1) 45, 45. doi: 10.1186/2045-3701-4-45

Epigenetic regulation in cancer progression

Funding

Current funding

  • 2025 - 2030
    Centre of Research Excellence to Improve the QuALIty of SurVival in Gynaecological Cancer PatiEnts (ALIVE WELL)
    NHMRC Centres of Research Excellence
    Open grant
  • 2024 - 2028
    ENDO3:A Phase III Randomised Controlled Clinical Trial Comparing Disease-Free Survival of Patients with or without Lymph Node Dissection in clinical stage I Endometrial Cancer (ANZGOGtrial #1911/2020)
    NHMRC Clinical Trials and Cohort Studies Grants
    Open grant

Supervision

Availability

Dr Eva Baxter is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Improving Quality of Survival for Women with Gynaecological Cancer

    Gynaecological cancers are the third most common cancer type diagnosed in Australian women. Each year over 6,700 Australian women and girls are diagnosed with gynaecological cancer and almost a third will not survive their disease.

    PhD scholarships are available for exceptional students to complete a PhD as part of a National Health and Medical Research Council Centre of Research Excellence (CRE) in Improving the Quality of Survival for Gynaecological Cancer Patients. The aim of this CRE is to address contemporary issues in gynaecological cancer care, with a focus on three priority areas: 1) enabling fertility after endometrial cancer; 2) reducing lymphoedema; and 3) optimising cancer recovery.

    We have three full-time PhD opportunities available focusing on improving quality of life, health, and function during and after gynaecological cancer treatment, with a focus on biomarker research, implementation research and cancer survivorship.

Supervision history

Current supervision

Media

Enquiries

Contact Dr Eva Baxter directly for media enquiries about:

  • Biomarkers
  • Endometrial cancer

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au